How can we best prevent suicide in young people? More questions than answers

shutterstock_166720643

Listening to a World Health Organisation podcast recently I learnt that someone dies as a result of suicide every 40 seconds; this equates to a million suicides each year. The podcast contains a myriad of such stark statistics and the contributors’ highlight how it is well established that young people are often at risk, and [read the full story…]

Expert review suggests that school-based depression and anxiety prevention programmes are effective in the short term

shutterstock_12040309

It is estimated that 20% of children up to the age of 18 will have suffered an emotional disorder of depression or anxiety (Costello et al., 2003). These two mental health conditions commonly occur together and can significantly influence daily functioning, relationships and education in this age group. Effective and evidence-based psychological treatments have been [read the full story…]

Treating antenatal depression could prevent offspring adult depression

shutterstock_120251488

Depression in late adolescence is a major public health concern, not least because it is strongly predictive of persistent, adult depression, which can have a severe effect on socioemotional functioning, education and employment. Increasingly, depression research is turning its attention to the matter of prevention of depression rather than exclusively focusing on treatment options and [read the full story…]

Cochrane review finds limited evidence to support valproate as a maintenance treatment for bipolar disorder

shutterstock_156614996

Bipolar disorder is an affective disorder marked by cycles between mania and depression. It has an early onset, with mean age ranging from 19 to 29 (Offord, 2012) and a prevalence of 0.5% – 4.3% in primary care alone, stretching to 9.3% in some settings (Cerimele, Chwastiak, Dodson, & Katon, 2013). With its problematic recurring [read the full story…]

D-cycloserine does not improve CBT for social anxiety disorder, but may accelerate early treatment gains

shutterstock_56516368

Clinical trials in the field of social anxiety to date have primarily focussed on the effect of either anxiolytic medication or cognitive behavioural therapy (CBT). At best these trials have demonstrated only moderate efficacy for either treatment independently (Davidson et al, 2004; Clark et al, 2003; Heimberg et al, 1998; Stein et al, 1998), and [read the full story…]

Largest RCT so far suggests that ketamine may be useful in the acute treatment of refractory depression

shutterstock_137892476

Major depression is a serious mental illness that often does not respond to mainstream drug treatment (antidepressants). In addition, there is usually a delay of 2-6 weeks before mood improves significantly. In situations like this, when at least two conventional antidepressants have been tried without success, depression is considered treatment-resistant. While multiple different strategies to [read the full story…]

The largest ever study of self-harm in prisons: prevalence, risk, clustering and subsequent suicide

shutterstock_79647754

New research published today in the Lancet shows that up to one in four women prisoners in England and Wales self-harm every year. The largest study of self-harm in prisons also reports that female prisoners are four times more likely to self-harm than male inmates. Previous systematic reviews have investigated self-harm in prisons (Lohner, 2007 and Dixon-Gordon, [read the full story…]

Digital innovation works best when users are involved at every stage

shutterstock_106935899

Digital mental health is thriving in 2013 and we are thrilled to be part of the growing community with our Mental Elf website and app. We have had time to reflect on the development of the Mental Elf website recently, as André was interviewed by Hannah Nicklin from Hide and Seek who had been asked to [read the full story…]

Is gabapentin a promising drug for the treatment of alcohol dependence?

shutterstock_132024347

Alcohol misuse is responsible for about 4% of all deaths annually, and in the UK it costs the NHS more than £3 billion per year.  A number of medications are currently licensed for the treatment of alcohol dependence. Unfortunately the medications don’t work for everyone and in the USA at least, fewer than 10% of [read the full story…]

Atomoxetine for adult ADHD: the harms outweigh the benefits, according to new systematic review

shutterstock_13076056

Attention Deficit Hyperactivity Disorder (ADHD) is a developmental neurological condition affecting functioning in a number of domains, but in particular, the ability to focus and concentrate, and regulate activity levels.  This is a common disorder with 2.5-4.0% of adults meeting diagnostic criteria for ADHD (Fayyad et al, 2007), and this condition has significant impact on a persons [read the full story…]